Collectively, these data suggestthat in AML, (1) the selection of initial therapy dynamically templates thelandscape of acquired resistance via modulation of MCL-1/BCL-XL and (2)appropriate selection of initial therapy may delay or altogether forestall theacquisition of resistance to ABT-199. Here, MCL1 is linked to acute myeloid leukemia.